Thiazolidinediones, dyslipidaemia and insulin resistance syndrome.
Insulin resistance is known to unite several metabolic abnormalities. The associated dyslipidaemia appears to play a central role in this atherogenic syndrome. Thiazolidinediones, which are recently introduced insulin sensitizing agents, have been shown to be effective not only in reducing elevated glucose levels, but also in improving the other metabolic abnormalities that are associated with insulin resistance. The present review focuses on these potential effects of thiazolidinediones.
Sunayama
S
S
Department of Cardiology, Juntendo University, Tokyo, Japan. snym@med.juntendo.ac.jp
Watanabe
Y
Y
Daida
H
H
Yamaguchi
H
H
D002839:Chromans / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D010641:Phenotype; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione; D000077288:Troglitazone; D005947:Glucose